NanoViricides Reports On The Highly Desirable Blood Concentration Profile Of Its Lead Clinical Stage Broad-spectrum Antiviral Agent NV-387 Upon Intravenous Administration In A Non-human Primate Animal Model
NanoViricides Reports On The Highly Desirable Blood Concentration Profile Of Its Lead Clinical Stage Broad-spectrum Antiviral Agent NV-387 Upon Intravenous Administration In A Non-human Primate Animal Model
nanoviricides報告其領先的臨牀前寬頻抗病毒劑NV-387於靜脈注射後在非人靈長動物模型中所具有的極佳血藥濃度曲線。
- The Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387, when given as a slow bolus intravenous infusion, resulted in a relatively flat plateau of blood concentration of the drug with very slow decline over a 24 hour period in a cynomolgus monkey model.
- The maximum concentration as well as the plateau concentration increased in a dose-dependent manner, as expected.
- 公司發現其領先的納米病毒滅活劑候選藥物NV-387，在猴模型中以緩慢注射靜脈輸注的方式給藥，導致藥物血濃度的平台相對平穩，在24小時內緩慢下降。
- 最大濃度以及平台濃度隨着劑量遞增而增加，符合預期。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。